Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New mineral spray shows promise for faster wound healing

NCT ID NCT07617961

Symptom relief Sponsor: Biointelligent Technology Systems SL Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study is testing a mineral-based spray called THERAVEX on 26 people with various wounds, including burns, pressure sores, and diabetic ulcers. The spray is used alongside standard wound care to see if it helps the skin heal better and faster. So far, it appears safe and may reduce swelling and improve tissue repair.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
THERAVEX Tissue Care Spray Plus (mineral-based topical spray)
What this could lead to
If successful, this spray could offer a safe, easy-to-use option to help heal wounds and burns faster, reducing pain and infection risk.
What could go wrong
This is a very small pilot study with only 26 people, so results may not apply to everyone. It is too early to know if it works better than standard care alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 26 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consisted of 26 adult patients presenting with different types of cutaneous lesions, including burns, traumatic wounds, pressure ulcers, diabetic ulcers, and chronic cutaneous wounds. Patients received standard wound care management combined with topical application of THERAVEX Tissue Care Spray Plus as an adjunctive supportive therapy. Clinical follow-up included routine medical evaluation and photographic documentation during the wound healing process.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Adult patients aged 18 years or older. Patients presenting with cutaneous wounds: burns, traumatic wounds, pressure ulcers, diabetic ulcers, or chronic cutaneous lesions. Patients considered clinically suitable for topical treatment with THERAVEX Tissue Care Spray Plus. Exclusion Criteria Known allergy or hypersensitivity to any component of THERAVEX Tissue Care Spray Plus. Presence of severe uncontrolled systemic infection requiring immediate surgical intervention. Participation in another interventional clinical study that could interfere with wound healing assessment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Burns are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

burn chronic ulcer of skin decubitus ulcer Diabetic Foot injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Burns Chronic wounds Diabetic foot ulcer Pressure ulcer Traumatic wounds

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Biointelligent Technology Syst

    RECRUITING

    Barcelona, 08009, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.